Addiction

• Overbaked: assessing and predicting acute adverse reactions to Cannabis (24 Sep 2024)
  
• Beliefs about cannabis at the time of legalization in Canada: results from a general population survey (24 Sep 2024)
  
• Cannabis as a Gateway Drug for Opioid Use Disorder (16 Sep 2024)
  
• Role of Cannabinoid CB2 Receptor in Alcohol Use Disorders: From Animal to Human Studies (25 Aug 2024)
  
• Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders (25 Aug 2024)
  
• New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders (21 Aug 2024)
  
• The Modulating Role of Sex and Anabolic-Androgenic Steroid Hormones in Cannabinoid Sensitivity (19 Aug 2024)
  
• Editorial: The Endocannabinoid System: Filling the Translational Gap Between Neuroscience and Psychiatry (05 Sep 2022)
  
• CB2 Receptor Involvement in the Treatment of Substance Use Disorders (05 Sep 2022)
  
• New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence (27 Aug 2022)
  
• Medical Cannabis in Pediatric Oncology: Friend or Foe? (05 Aug 2022)
  
• Medicinal Cannabis and Central Nervous System Disorders (31 Jul 2022)
  
• The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients - Journal of Cannabis Research (26 Jul 2022)
  
• ICRS 2019: CBD for Anxiety, Cancer, Heart Disease, Addiction... (21 Jul 2022)
  
• CBD and THC are Safe Supplements to Opioid Treatment (18 Jul 2022)